PRINT24.COM
15.6.2016 10:05:08 CEST | Business Wire | Press release
The online printer UNITEDPRINT SE – to which one of its most well-known brands, print24.com, belongs – is extending its product range to include Thread-stitched Books and ultralight Flyers, and will also be offering posters in single quantities in A0 and A1 formats. In addition, the already attractive prices for Folded flyers in quantities of 50,000 und Brochures with Perfect binding starting from 2,500 pieces will be reduced by a further 10%.
Ali Jason Bazooband, Managing Director for Innovation/Marketing of UNITEDPRINT SE, says:
“We receive daily requests from customers for new products and services, and we strive to offer these as quickly and cost-effectively as possible. I’m therefore very excited to be able to now also offer our customers Books with Thread-stitching, which in comparison to our Books with Perfect binding, are up to 50% less expensive. Furthermore, we have supplemented our product range to include ultralight Flyers of 70 gsm and 90 gsm and Posters in single quantities in A0 and A1 formats. We have also been able to reduce the price of our Top sellers by 10%, such as the 135 gsm Folded flyers in A4 and A5 formats starting from 50,000 pieces, and A4 and A5 Brochures with Perfect binding in quantities from 2,500.”
In comparison to Books with Perfect binding, Books with Thread-stitching are clearly more durable and of higher quality. They can be ordered from print24.com in single quantities or more. With their extremely low weight of 70 gsm or 90 gsm, the ultralight Flyers are ideal for reducing postage costs and perfect as advertising inserts. Posters in single quantities in A0 and A1 formats are in high demand for use as advertising support such as customer stoppers and displays.
print24.com is a UNITEDPRINT SE brand, a global and innovation-oriented e-commerce company for print and media. As one of Europe’s leading online printers, UNITEDPRINT SE is represented in the marketplace by the renowned brands print24, Easyprint, Unitedprint, getprint, printwhat, FIRSTPRINT, DDK PRINT BIG, infowerk, and Unitedprint Shop Services (USS). The company employs a staff of over 700 people at 26 locations worldwide (in Germany, 21 other European countries, and in Brazil, China, Canada, and the US). In addition to the standard print products, the company provides its customers with high-quality products ranging from the textile printing, photo printing, advertising equipment printing and gastronomy sectors. Customers can also benefit from their 24-hour availability as well as their 30/60/90-payment model, which is unique in this sector.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160615005490/en/
Contact:
unitedprint.com SE
Maria Lehmann
0049 (0)351 / 27225388
presse@unitedprint.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release
Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a
Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release
Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom